Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Killock

Showing results (91-100 of 304) with videos related to

Pageof 31
Sort By:
Nature Reviews. Clinical Oncology|May 25, 2021
HCL - vemurafenib plus rituximab holds promiseDavid Killock
Nature Reviews. Clinical Oncology|December 14, 2016
Gynaecological cancer: PARP inhibition - moving beyond BRCA-mutated diseaseDavid Killock
Nature Reviews. Clinical Oncology|March 30, 2017
Haematological cancer: Anti-PD-1 therapy with nivolumab after allo-HSCT for Hodgkin lymphomaDavid Killock
Nature Reviews. Clinical Oncology|March 20, 2014
Targeted therapies: Imatinib prior to allogeneic HSCT therapy improves both relapse and nonrelapse survival in patients with Ph+ ALLDavid Killock
Nature Reviews. Clinical Oncology|February 27, 2014
Cancer therapy: could vitamin C be a useful adjunct to chemotherapy?David Killock
Nature Reviews. Clinical Oncology|February 22, 2017
Gynaecological cancer: SLN staging for endometrial cancerDavid Killock
Nature Reviews. Clinical Oncology|February 8, 2017
Prostate cancer: Improving diagnosis - can MP-MRI fulfil its PROMIS?David Killock
Nature Reviews. Clinical Oncology|September 6, 2022
Synergy of EphB2 and PD-1 blockadeDavid Killock
Nature Reviews. Clinical Oncology|October 25, 2018
BCC identity switch breaks restraints of Hedgehog pathway inhibitionDavid Killock
Nature Reviews. Urology|May 14, 2014
Imaging: fMRI developments promise understanding of voiding dysfunctionDavid Killock
Pageof 31

Showing results (91-100 of 304) with videos related to

Sort By:
Pageof 31
Nature Reviews. Clinical Oncology|May 25, 2021
HCL - vemurafenib plus rituximab holds promiseDavid Killock
Nature Reviews. Clinical Oncology|December 14, 2016
Gynaecological cancer: PARP inhibition - moving beyond BRCA-mutated diseaseDavid Killock
Nature Reviews. Clinical Oncology|March 30, 2017
Haematological cancer: Anti-PD-1 therapy with nivolumab after allo-HSCT for Hodgkin lymphomaDavid Killock
Nature Reviews. Clinical Oncology|March 20, 2014
Targeted therapies: Imatinib prior to allogeneic HSCT therapy improves both relapse and nonrelapse survival in patients with Ph+ ALLDavid Killock
Nature Reviews. Clinical Oncology|February 27, 2014
Cancer therapy: could vitamin C be a useful adjunct to chemotherapy?David Killock
Nature Reviews. Clinical Oncology|February 22, 2017
Gynaecological cancer: SLN staging for endometrial cancerDavid Killock
Nature Reviews. Clinical Oncology|February 8, 2017
Prostate cancer: Improving diagnosis - can MP-MRI fulfil its PROMIS?David Killock
Nature Reviews. Clinical Oncology|September 6, 2022
Synergy of EphB2 and PD-1 blockadeDavid Killock
Nature Reviews. Clinical Oncology|October 25, 2018
BCC identity switch breaks restraints of Hedgehog pathway inhibitionDavid Killock
Nature Reviews. Urology|May 14, 2014
Imaging: fMRI developments promise understanding of voiding dysfunctionDavid Killock
Pageof 31